KRAS and TP53 mutations have been identified as major driver oncogenes in various cancer tissues, including biliary tract cancer, lung cancer, pancreatic ductal carcinoma, colorectal carcinoma, and laryngeal cancer [3,16,17,19,38,39,40,41,42]. This evidence concerns the gene KRAS and lung carcinoma.